Thus, the initial hope that the identification of HIV-specific elements of the immune system in HIV-infected individuals would lead to better therapies and vaccines has been replaced by the ...
Objective Both belimumab and telitacicept are recognised blockers for B lymphocyte activation, both of which have been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback